One in three of us will get cancer and increases in life expectancy indices will exacerbate this statistic in the future. Most current chemotherapeutics have devastating side effects including hair loss, nausea, weakened immunity and fatigue to name but a few.

BioMoti exists to transform the treatment of cancer patients by doing things differently. BioMoti seeks to transform the treatment of cancer by targeted delivery of therapeutics to the intracellular space of cancer cells; aiming to dramatically increase efficacy whilst reducing side effects.

Oncojans™ are a new class of therapeutic microparticles that target and gain entry to the interior of cancer cells where they slowly release drugs at the point of need whilst sparing healthy tissue. The Oncojan™ platform is compatible with a range of drug classes from small molecule therapeutics to larger biologicals.

MOTI1001 is BioMoti’s lead Oncojan™ based ovarian cancer candidate that has shown very promising potential in early preclinical studies.


Targeted delivery of therapeutics to the interior of cancer cells

Company type
Dr Davidson Ateh
LinkedIn logo Chief Executive Officer 

BioPartner UK, BIA, One Nucleus

The UK BioIndustry Association and One Nucleus are your UK points of contact at Biotech Showcase 2014, representing BioPartner and supporting the UK group.

BioPartner is an independent, accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. Through the BioPartnership Programme, BioPartner assists companies to attend major international biopharma conferences by providing access to government grants and heavily discounted entry fees.

Mr Ted Agne
LinkedIn logo Advisor 
Dr Tony Jones
LinkedIn logo
Dr Steve Bates
LinkedIn logo

Biotec Services International

Company type
Doug Basinger